Molecular profiles of endometrial cancer tumors among Black patients

• Published in: Gynecologic oncology Vol. 166; no. 1; pp. 108 - 116
• Main Authors: Wilhite, Annelise M., Baca, Yasmine, Xiu, Joanne, Paladugu, Rajesh, ElNaggar, Adam C., Brown, Jubilee, Winer, Ira S., Morris, Robert, Erickson, Britt K., Olawaiye, Alexander B., Powell, Matthew, Korn, W. Michael, Rocconi, Rodney P., Khabele, Dineo, Jones, Nathaniel L.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-07-2022
• Subjects: Black People; Carcinoma, Endometrioid - genetics; Carcinoma, Endometrioid - pathology; Carcinosarcoma - genetics; Carcinosarcoma - pathology; Disparities; Endometrial cancer; Endometrial Neoplasms - pathology; Female; Humans; Microsatellite Instability; Molecular profiling; Mutation; Endometrial cancer; Molecular profiling; Disparities
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1016/j.ygyno.2022.04.014

Disparate outcomes exist between Black and White patients with endometrial cancer (EC). One contributing factor is the disproportionately low representation of Black patients in clinical trials and in tumor molecular profiling studies. Our objective was to investigate molecular profiles of ECs in a cohort with a high proportion of tumors from Black patients.
A total of 248 EC samples and self-reported race data were collected from 6 institutions. Comprehensive tumor profiling and analyses were performed by Caris Life Sciences.
Tumors from 105 (42%) Black and 143 (58%) White patients were included. Serous histology (58% vs 36%) and carcinosarcoma (25% vs 16%), was more common among Black patients, and endometrioid was less common (17% vs 48%) (p < 0.01). Differences in gene mutations between cohorts corresponded to observed histologic differences between races. Specifically, TP53 mutations were predominant in serous tumors. In endometrioid tumors, mutations in ARID1A were the most common, and high rates of MSI-H, MMRd, and TMB-H were observed. In carcinosarcoma tumors, hormone receptor expression was high in tumors of Black patients (PR 23.4%, ER 30.8%). When stratified by histology, there were no significant differences between tumors from Black and White women.
This cohort had a high proportion of tumors from Black women. Distinct molecular profiles were driven primarily by more aggressive histologic subtypes among Black women. Continued effort is needed to include Black women and other populations under-represented in EC molecular profiling studies as targeted therapies and personalized medicine become mainstream.
•Black patients with endometrial cancer (EC) have worse outcomes than White patients.•The use of molecular profiling and targeted therapies in EC is increasing.•To comprehensively study molecular profiles of EC, we need adequate representation of tumors from Black patients.•This study investigates molecular profiles of tumors from a cohort with a high proportion of tumors from Black patients.